Development and Optimization of a Cilostazol-Loaded Nanomicelle Transdermal Patch for Hypertension Management.

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2025-07-16 DOI:10.2174/0122117385362916250630053000

Vaishali Thakkar, Prima Patel, Khyati Parekh, Hardik Rana, Bhupendra Prajapati

{"title":"Development and Optimization of a Cilostazol-Loaded Nanomicelle Transdermal Patch for Hypertension Management.","authors":"Vaishali Thakkar, Prima Patel, Khyati Parekh, Hardik Rana, Bhupendra Prajapati","doi":"10.2174/0122117385362916250630053000","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to develop and optimize a cilostazol-loaded nanomicelle transdermal patch to enhance solubility, stability, and controlled drug release.Objective: To improve cilostazol bioavailability by formulating a stable, nanomicelle-loaded transdermal patch.Methods: Nanomicelles were prepared using the thin-film hydration method with Soluplus and Poloxamer 188 as the polymer and surfactant. The transdermal patch was fabricated using the solvent casting method and evaluated for tensile strength, folding endurance, and in vitro drug diffusion.Results: The optimized formulation showed 97.71% entrapment efficiency, 48.86% drug loading, a particle size of 129.07 nm, and a zeta potential of -21.5 mV. The patch exhibited a tensile strength of 141.83 MPa, folding endurance of over 300 folds, and sustained in vitro drug diffusion.Conclusion: The developed transdermal patch offers a promising strategy to enhance cilostazol bioavailability by bypassing first-pass metabolism, promoting better penetration, and ensuring improved patient compliance.","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385362916250630053000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to develop and optimize a cilostazol-loaded nanomicelle transdermal patch to enhance solubility, stability, and controlled drug release.

Objective: To improve cilostazol bioavailability by formulating a stable, nanomicelle-loaded transdermal patch.

Methods: Nanomicelles were prepared using the thin-film hydration method with Soluplus and Poloxamer 188 as the polymer and surfactant. The transdermal patch was fabricated using the solvent casting method and evaluated for tensile strength, folding endurance, and in vitro drug diffusion.

Results: The optimized formulation showed 97.71% entrapment efficiency, 48.86% drug loading, a particle size of 129.07 nm, and a zeta potential of -21.5 mV. The patch exhibited a tensile strength of 141.83 MPa, folding endurance of over 300 folds, and sustained in vitro drug diffusion.

Conclusion: The developed transdermal patch offers a promising strategy to enhance cilostazol bioavailability by bypassing first-pass metabolism, promoting better penetration, and ensuring improved patient compliance.

查看原文本刊更多论文

用于高血压治疗的西洛他唑纳米胶束透皮贴剂的研制与优化。

背景：本研究旨在开发并优化载西洛他唑纳米胶束透皮贴剂，以提高其溶解度、稳定性和药物控释。目的：制备稳定的纳米微球透皮贴剂，提高西洛他唑的生物利用度。方法：以Soluplus和poloxam188为聚合物和表面活性剂，采用薄膜水化法制备纳米胶束。采用溶剂铸造法制备透皮贴片，并对其拉伸强度、折叠耐久性和体外药物扩散进行了评价。结果：优化后的配方包封率为97.71%，载药量为48.86%，粒径为129.07 nm， zeta电位为-21.5 mV。该贴片抗拉强度为141.83 MPa，折叠次数超过300次，并能持续体外药物扩散。结论：所开发的透皮贴片通过绕过第一次代谢，促进更好的渗透，并确保提高患者的依从性，从而提高西洛他唑的生物利用度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.